There are different ways to measure how Medicare Shared Savings Program (MSSP) accountable care organizations (ACOs) have saved money, and the way used can drastically affect the amount of savings reported, explained Clif Gaus, ScD, president and CEO of the National Association of ACOs.
There are different ways to measure how Medicare Shared Savings Program (MSSP) accountable care organizations (ACOs) have saved money, and the way used can drastically affect the amount of savings reported, explained Clif Gaus, ScD, president and CEO of the National Association of ACOs.
Transcript
NAACOS recently released a study about how much MSSP ACOs are savings, and the findings differ greatly from what CMS has reported but are in line with research out of Harvard. What are the savings NAACOS found and what is the controversy around how to measure savings?
So, there are really are 2 ways of measuring costs and performance. The first way is the MSSP benchmark way. The benchmarks are set based on historical costs, and over a 3-year period, and then trended forward for the performance year. However, those benchmarks are capped in terms of when risk changes and goes up, the benchmark doesn’t go up. So, the patients may become sicker in the subsequent years, and cost more, but the benchmark doesn’t increase. So, ACOs are against a much harder goal or bar of performance, and therefore not always achieving as much savings as much as they truly are.
The other way of measuring is to compare precisely the ACO beneficiaries based on their risk, based on their geography, their age, and match those beneficiaries to a control group of beneficiaries who are not in the ACO, but who are living in the same geographic area, have the same illnesses, etc. And when you compare those 2 groups—the ACO beneficiaries and the like nonbeneficiaries—over time, what you see is that the ACO beneficiaries’ costs are substantially lower than the control group by almost 2-fold.
So, CMS based on benchmarks was showing gross savings of, I think it was in the range of $900 million from 2013, 2014, 2015. But when you compare them to the savings from the control group, those savings were $1.8 billion. So, the savings essentially based upon that match control group are twice what CMS was estimating.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More